• <center id="my6c6"></center>
    <rt id="my6c6"><acronym id="my6c6"></acronym></rt>
  • <abbr id="my6c6"></abbr>
  •  

    上海強世信息科技有限公司

    Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients.
    作者:Yoshihara K1, Gao Y, Shiga H, Wada DR, Hisaoka M. | 發布:Yuting Yang | 發布時間: 2018-09-10 | 1251 次瀏覽 | 分享到:
    Abstract

    BACKGROUND:
    Olmesartan medoxomil (CS-866) is a new orally active angiotensin II receptor antagonist that is highly selective for the AT1 receptor subtype.

    OBJECTIVE:
    To develop a population pharmacokinetic model for olmesartan (RNH-6270), the active metabolite of olmesartan medoxomil, in healthy volunteers and hypertensive patients, and to evaluate effects of covariates on the apparent oral clearance (CL/F), with particular emphasis on the effect of race.

    DESIGN:
    Retrospective analysis of data from 12 phase I-III trials in the US, Europe and Japan.

    PARTICIPANTS:
    Eighty-nine healthy volunteers and 383 hypertensive patients.

    METHODS:
    Nonlinear mixed-effects modelling was used to evaluate 7911 olmesartan plasma sample concentrations. The covariates included age, bodyweight, sex, race (Westerners [including Caucasians and Hispanics] versus Japanese), patient status (hypertensive patients versus healthy volunteers), serum creatinine level as an index of renal function and serum chemistry data as indices of hepatic function.

    RESULTS:
    The pharmacokinetic data of olmesartan were well described by a two-compartment linear model with first-order absorption and an absorption lag-time, parameterised in terms of CL/F (6.66 L/h for a typical male Western hypertensive patient), absorption rate constant (1.46h-1), elimination rate constant (0.193h-1), rate constant from the central to peripheral compartment (0.061h-1), rate constant from the peripheral to central compartment (0.079h-1) and absorption lag-time (0.427h). Analysis of covariates showed that age, bodyweight, sex, patient status and renal function were factors influencing the clearance of olmesartan.

    CONCLUSION:
    The population pharmacokinetic analysis of olmesartan showed that: (i) severe renal impairment (serum creatinine >265 micromol/L [approximately 3 mg/dL]) could cause a clearance decrease of > or =30%; (ii) older age, lower bodyweight and being female were determinants of lower clearance but their effects on olmesartan clearance were within 20%; (iii) no statistically significant difference in clearance was found between Westerners and Japanese.
    狠狠综合久久av一区二区| 久久国产劲暴∨内射| 精品伊人久久大线蕉色首页| 狠狠色婷婷久久一区二区| 色综合久久中文字幕| 久久综合给合久久狠狠狠97色69| 久久综合视频网站| 国产精品美女久久久网站| 色婷婷综合久久久| 久久中文字幕视频| 亚洲精品乱码久久久久66| 青青草原综合久久大伊人导航| 色婷婷综合久久久| 久久丫精品国产亚洲av| 亚洲成色www久久网站夜月| 久久精品成人免费观看97| 秋霞日韩久久理论电影| 亚洲AV成人无码久久WWW| 亚洲精品乱码久久久久久下载| 久久本网站受美利坚法律保护 | 色综合久久无码五十路人妻| 久久99热国产这有精品| 久久午夜综合久久| 久久精品免费大片国产大片| 日本久久久久久久| 青草久久精品亚洲综合专区| 久久久久久久91精品免费观看| 久久天天躁夜夜躁狠狠| 久久久久99精品成人片直播| 色88久久久久高潮综合影院| 久久大香伊蕉在人线国产h| 狠狠色丁香久久综合婷婷| 思思久久精品在热线热| 91精品国产综合久久精品| 久久久噜噜噜久久中文字幕色伊伊| 一级做性色a爰片久久毛片免费| 成人久久伊人精品伊人| 国产精品久久二区二区| 国产精品一区二区久久乐下载| 久久精品国产亚洲av天美18| 狠狠综合久久久久综合小说网|